A randomized controlled trial of vaginal progesterone for luteal phase support in modified natural cycle - frozen embryo transfer

Gynecol Endocrinol. 2021 Sep;37(9):792-797. doi: 10.1080/09513590.2020.1854717. Epub 2020 Dec 14.

Abstract

Objective: Our aim was to study whether luteal phase support (LPS) increases the live-birth rate (LBR) in women undergoing modified natural cycle (mNC) frozen-thawed embryo transfer (FET).

Methods: In a randomized controlled trial, conducted at a university-affiliated tertiary medical center, a total of 59 patients aged 18-45 years, underwent mNC-FET. FET was performed in mNC following ovulation triggering by hCG. Patients were randomized into two groups; The No-LPS Group included 28 women who did not receive LPS, and the LPS Group included 31 women who received vaginal progesterone for LPS. The main outcome measure was LBR.

Results: Baseline demographic and clinical characteristics were comparable between the study groups. The no-LPS group and the LPS group did not differ with regard to clinical pregnancy rate (21.4% vs. 32.3%; respectively, p = .35), LBR (17.9% vs. 19.4%; respectively, p = .88), or spontaneous miscarriage rate (3.6% vs. 12.9%; respectively, p = .35). On multivariate logistic regression analysis, LPS was not associated with LBR after controlling for confounders.

Conclusion: The results of our study suggest that LPS after mNC-FET does not improve the reproductive outcome, and therefore, might not be necessary.C linicaltrials.gov identifier: NCT01483365.

Keywords: ART; Frozen embryo transfer; RCT; luteal phase support; modified natural cycle.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Abortion, Spontaneous / epidemiology
  • Administration, Intravaginal
  • Adult
  • Cryopreservation*
  • Embryo Transfer / methods*
  • Female
  • Fertilization in Vitro / methods*
  • Humans
  • Live Birth
  • Luteal Phase / physiology*
  • Pregnancy
  • Pregnancy Rate
  • Progesterone / administration & dosage*
  • Reproductive Techniques, Assisted

Substances

  • Progesterone

Associated data

  • ClinicalTrials.gov/NCT01483365